Literature DB >> 10506572

Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole.

D A Hess1, M E Sisson, H Suria, J Wijsman, R Puvanesasingham, J Madrenas, M J Rieder.   

Abstract

Treatment with sulfonamide antibiotics in HIV-infected patients is associated with a high incidence (> 40%) of adverse drug events, including severe hypersensitivity reactions. Sulfonamide reactive metabolites have been implicated in the pathogenesis of these adverse reactions. Sulfamethoxazole hydroxylamine (SMX-HA) induces lymphocyte toxicity and suppression of proliferation in vitro; the mechanism(s) of these immunomodulatory effects remain unknown. We investigated the cytotoxicity of SMX-HA via apoptosis on human peripheral blood mononuclear cells and purified cell subpopulations in vitro. CD19(+), CD4(+), and CD8(+) cells were isolated from human peripheral blood by positive selection of cell surface molecules by magnetic bead separation. SMX-HA induced significant CD8(+) cell death (67 +/- 7%) at 100 microM SMX-HA, with only minimal CD4(+) cell death (8 +/- 4%). No significant subpopulation toxicity was shown when incubated with parent drug (SMX). Flow cytometry measuring phosphatidylserine externalization 24 h after treatment with 100 microM and 400 microM SMX-HA revealed 14.1 +/- 0.7% and 25. 6 +/- 4.2% annexin-positive cells, respectively, compared to 3.7 +/- 1.2% in control PBMCs treated with 400 microM SMX. Internucleosomal DNA fragmentation was observed in quiescent and stimulated PBMCs 48 h after incubation with SMX-HA. Our data show that CD8(+) cells are highly susceptible to the toxic effects of SMX-HA through enhanced cell death by apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506572     DOI: 10.1096/fasebj.13.13.1688

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

1.  Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; C Burkhart; A E Cribb; W J Pichler; B K Park
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  HIV Tat potentiates cell toxicity in a T cell model for sulphamethoxazole-induced adverse drug reactions.

Authors:  Kemi Adeyanju; Adriana Krizova; Philippe A Gilbert; Gregory A Dekaban; Michael Rieder
Journal:  Virus Genes       Date:  2009-03-10       Impact factor: 2.332

3.  RNA expression profiling in sulfamethoxazole-treated patients with a range of in vitro lymphocyte cytotoxicity phenotypes.

Authors:  Jennifer M Reinhart; Warren Rose; Daniel J Panyard; Michael A Newton; Tyler K Liebenstein; Jeremiah Yee; Lauren A Trepanier
Journal:  Pharmacol Res Perspect       Date:  2018-03-02

4.  Trimethoprim-sulfamethoxazole-induced Steven Johnson syndrome in an HIV-infected patient.

Authors:  Syed Ahmed Taqi; Syed Ahmed Zaki; Angadi Rajasab Nilofer; Lateef Begum Sami
Journal:  Indian J Pharmacol       Date:  2012 Jul-Aug       Impact factor: 1.200

Review 5.  Sulfonamide allergy and cross-reactivity.

Authors:  Carolyn C Brackett
Journal:  Curr Allergy Asthma Rep       Date:  2007-04       Impact factor: 4.919

6.  An Adverse Drug Reaction to Trimethoprim-Sulfamethoxazole Revealing Primary HIV: A Case Report and Literature Review.

Authors:  Charles Meyer; Nicole Behm; Emily Brown; Nathanial K Copeland; Marvin J Sklar
Journal:  Case Rep Infect Dis       Date:  2015-12-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.